Fig. 4

Immunotherapy of melanoma B16-F10 based on the synergy of R-848 and mannan-SMCC. Further improvement using poly(I:C) and anchored L. monocytogenes. Tumor transplantation and measurement was performed as described in Fig. 1. Six mice were used per group. Therapies, based on intratumoral application of corresponding preparations (50 microliters/mouse), started 12 days after tumor transplantation. Four therapeutic pulses were applied on days 0, 1, 2…8, 9, 10…16, 17, 18…24, 25, 26. Therapeutic mixture contained following concentrations of active parts dissolved in PBS: 1 billion L. monocytogenes-SMCC/ml, 0.5 mg R-848, HCl form/ml, 0.5 mg poly(I:C)/ml, 0.2 mM mannan-SMCC, PBS was used as control. a The effect of therapy on tumor growth. * P ≤ 0.05 ** P ≤ 0.01 *** P ≤ 0.005 **** P ≤ 0.001 ***** P ≤ 0.0005 compared to control (PBS). b Survival analysis. a – L.m.-SMCC + man-SMCC. b – L.m.-SMCC + R-848 + man-SMCC. c – L.m.-SMCC + R-848 + poly(I:C) + man-SMCC. d – R-848 + man-SMCC. e – R-848 + poly(I:C) + man-SMCC. f – PBS (control). b versus f ….. P ≤ 0.005. c versus f ….. P ≤ 0.01. d versus f ….. P ≤ 0.05. e versus f ….. P ≤ 0.05